BRIDGEWATER, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced positive clinical outcomes for V-Go compared to insulin pen devices for treating people with type 2 diabetes prescribed basal-bolus insulin therapy. The results were presented at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019) in Berlin, Germany.
This retrospective study was performed using electronic medical records of 148 patients from nine diabetes centers in the United States. Patients with uncontrolled blood sugar levels (A1c ≥ 7.0%) who were prescribed basal-bolus insulin therapy administered by insulin pen devices prior to using V-Go were included in the evaluation. At the third and seventh month of V-Go use, patients experienced statistically significant reductions in both A1c levels and total daily doses of insulin. A1c levels decreased by 1.04 and 1.11, respectively from a baseline A1c of 9.1%. The average total daily dose of insulin decreased by 25 and 24 units per day, respectively from a baseline dose of 82 units per day. Similar A1c reductions were experienced in patients prescribed > 50 units per day of basal or prandial insulin at baseline.
“We are excited to share these positive data from our clinical study at ATTD 2019,” said John Timberlake, President and Chief Executive Officer of Valeritas. “We believe the results of this study further support when basal-bolus insulin therapy is needed, the use of V-Go Wearable Insulin Delivery device can offer significant clinical benefit.”
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.
More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.
Forward-Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Statements or claims made by third parties regarding the efficacy or functionality of V-Go as compared to other products are statements made by such individual and should not be taken as evidence of clinical trial results supporting such statements or claims. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.
Investor Contacts:
Lynn Pieper Lewis or Greg Chodaczek
Gilmartin Group
646-924-1769
ir@valeritas.com
Media Contact:
Kevin Knight
Knight Marketing Communications, Ltd.
206-451-4823
pr@valeritas.com